Back to funds

Trails Edge Capital Partners, LP

Updated 6 days ago

Managed by Trails Edge Capital Partners, Lp • Latest filing Q3 2026

Portfolio value
$695.9M
Q3 2026
Filings
4
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
—
Implied from 13F holdings

Portfolio value history

13F-disclosed portfolio value over 4 quarters

Show data table
PeriodPortfolio value
Q4 2025$404.7M
Q1 2026$436.5M
Q2 2026$629.9M
Q3 2026$695.9M

Top holdings

38 positions as of Q3 2026

View filing
L

LB PHARMACEUTICALS INC

Value
$44.1M
Shares
1.15M
% Port
6.34%
B

BIOMARIN PHARMACEUTICAL INC

Value
$40M
Shares
667.0K
% Port
5.75%
N

NURIX THERAPEUTICS INC

Value
$37.3M
Shares
1.57M
% Port
5.36%
O

OBSIDIAN THERAPEUTICS INC

Value
$34.3M
Shares
2.50M
% Port
4.92%
I

IMMUNOCORE HLDGS PLC

Value
$32.2M
Shares
1.06M
% Port
4.63%
F

4D MOLECULAR THERAPEUTICS IN

Value
$31.9M
Shares
2.23M
% Port
4.58%
D

DESIGN THERAPEUTICS INC

Value
$31.4M
Shares
2.50M
% Port
4.52%
C

CYTOKINETICS INC

Value
$31M
Shares
470.0K
% Port
4.45%
T

FIRST TRACKS BIOTHERAPEUTICS

Value
$28.8M
Shares
814.0K
% Port
4.15%
F

FAETH THERAPEUTICS INC

Value
$28M
Shares
941.7K
% Port
4.02%
T

TANGO THERAPEUTICS INC

Value
$27.4M
Shares
1.10M
% Port
3.94%
N

NEUROGENE INC

Value
$26.8M
Shares
964.9K
% Port
3.86%
C

CELLDEX THERAPEUTICS INC NEW

Value
$24.8M
Shares
765.0K
% Port
3.56%
A

AVALO THERAPEUTICS INC

Value
$23M
Shares
1.50M
% Port
3.30%
C

CONTINEUM THERAPEUTICS INC

Value
$22.7M
Shares
1.69M
% Port
3.27%
T

TYRA BIOSCIENCES INC

Value
$21.9M
Shares
1.00M
% Port
3.14%
M

MOONLAKE IMMUNOTHERAPEUTICS

Value
$19.7M
Shares
1.68M
% Port
2.82%
I

INHIBIKASE THERAPEUTICS INC

Value
$18.7M
Shares
9.11M
% Port
2.69%
I

INHIBRX BIOSCIENCES INC

Value
$17M
Shares
170.0K
% Port
2.44%
X

XENON PHARMACEUTICALS INC

Value
$14.9M
Shares
400.0K
% Port
2.14%

Explore